BioSpace News Archive

Policy

Cancer Drug Manufacturer Intas Slapped with FDA Warning Letter

Following reports of destroyed and discarded data, the U.S. regulator issued a warning letter to India’s Intas Pharmaceuticals regarding violations of current good manufacturing practice.

August 2, 2023
·
2 min read
·
Tristan Manalac
Business

Vertex Raises Cystic Fibrosis Sales Forecast Amid Strong Trikafta Demand

The biopharma company reported sales of $2.24 billion in the second quarter for the cystic fibrosis treatment, beating analysts’ estimate, after it won FDA approval in children ages two to five in April.

August 2, 2023
·
2 min read
·
Nick Paul Taylor
Drug Development

GLP-1 Drugs Show Promise in Alcohol, Opioid Use Disorders

Early research and anecdotal evidence indicate that the popular diabetes and obesity drugs could treat some patients with addictive disorders.

August 2, 2023
·
5 min read
·
Heather McKenzie
Business

Illumina, Guardant Dismiss Litigation and Extend Commercial Relationship

Following a year-long legal battle, Illumina is dropping the intellectual property allegations against Guardant. The companies have also entered into a new long-term purchase and supply commitment.

August 2, 2023
·
2 min read
·
Kate Goodwin
Policy

GSK Sues Pfizer for Alleged RSV Vaccine Patent Infringement

The lawsuit alleges that Pfizer infringed GSK’s patents on respiratory syncytial virus shots. The complaint comes just months after both companies had their respective RSV vaccines approved.

August 2, 2023
·
1 min read
·
David Adam
Business

PacBio Announces Second Quarter 2023 Financial Results

PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2023.

August 2, 2023
·
16 min read
Lone Star Bio

Natera to Participate in Canaccord Genuity 43rd Annual Growth Conference

Natera, Inc. announced that members of its leadership team will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, Aug. 9 at 4:30 pm ET | 1:30 pm PT in Boston, MA.

August 2, 2023
·
1 min read
Business

Paragon 28 Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Net Revenue Guidance

Paragon 28, Inc., a leading medical device company exclusively focused on the foot and ankle orthopedic market, reported financial results for the quarter ended June 30, 2023 and reaffirmed its 2023 net revenue guidance.

August 2, 2023
·
14 min read
Business

Evolus Reports Second Quarter 2023 Results and Provides Business Update

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results for the second quarter ended June 30, 2023 and provided a business update.

August 2, 2023
·
18 min read
Business

Sarepta Therapeutics Announces Second Quarter 2023 Financial Results and Recent Corporate Developments

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter 2023.

August 2, 2023
·
43 min read